{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T17:10:38Z","timestamp":1758820238838,"version":"3.41.2"},"reference-count":33,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1097\/igc.0b013e3182a1cf71","type":"journal-article","created":{"date-parts":[[2013,8,22]],"date-time":"2013-08-22T10:48:02Z","timestamp":1377168482000},"page":"1406-1410","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Added Value of Family History in Counseling About Risk of BRCA1\/2 Mutation in Early-Onset Epithelial Ovarian Cancer"],"prefix":"10.1016","volume":"23","author":[{"given":"Marieke Arts-de","family":"Jong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catharina M.","family":"Manders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicoline","family":"Hoogerbrugge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjolijn J.L.","family":"Ligtenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leon F.","family":"Massuger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne A.","family":"de Hullu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liesbeth","family":"Spruijt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1097\/IGC.0b013e3182a1cf71_bb0005","first-page":"609","article-title":"Ovarian cancer: an overview","volume":"80","author":"Roett","year":"2009","journal-title":"Am Fam Physician"},{"issue":"suppl 1","key":"10.1097\/IGC.0b013e3182a1cf71_bb0010","first-page":"S161","article-title":"Carcinoma of the ovary. FIGO 26th annual report on the results of treatment in gynecological cancer","volume":"95","author":"Heintz","year":"2006","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1097\/IGC.0b013e3182a1cf71_bb0015","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ygyno.2010.06.003","article-title":"SGO white paper on ovarian cancer: etiology, screening and surveillance","volume":"119","author":"Schorge","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1097\/IGC.0b013e3182a1cf71_bb0020","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1471-0528.1998.tb10148.x","article-title":"A systematic review and meta-analysis of family history and risk of ovarian cancer","volume":"105","author":"Stratton","year":"1998","journal-title":"BrJ Obstet Gynaecol"},{"key":"10.1097\/IGC.0b013e3182a1cf71_bb0025","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s10689-012-9518-6","article-title":"Adequacy of family history taking in ovarian cancer patients: a population-based study","volume":"11","author":"van Altena","year":"2012","journal-title":"Fam Cancer"},{"key":"10.1097\/IGC.0b013e3182a1cf71_bb0030","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/IGC.0b013e3182392714","article-title":"Family history and women with ovarian cancer: is it asked and does it matter? An observational study","volume":"22","author":"Lanceley","year":"2012","journal-title":"Int J Gynecol Cancer"},{"key":"10.1097\/IGC.0b013e3182a1cf71_bb0035","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","article-title":"BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group","volume":"30","author":"Alsop","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1097\/IGC.0b013e3182a1cf71_bb0040","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ygyno.2011.01.020","article-title":"Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer","volume":"121","author":"Zhang","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1097\/IGC.0b013e3182a1cf71_bb0045","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1086\/318787","article-title":"Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer","volume":"68","author":"Risch","year":"2001","journal-title":"Am JHum Genet"},{"key":"10.1097\/IGC.0b013e3182a1cf71_bb0050","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.critrevonc.2008.06.003","article-title":"Hereditary ovarian cancer","volume":"69","author":"Russo","year":"2009","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1097\/IGC.0b013e3182a1cf71_bb0055","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1200\/JCO.2006.09.1066","article-title":"Meta-analysis of BRCA1 and BRCA2 penetrance","volume":"25","author":"Chen","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1097\/IGC.0b013e3182a1cf71_bb0060","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1001\/jama.2012.20","article-title":"Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer","volume":"307","author":"Bolton","year":"2012","journal-title":"JAMA"},{"key":"10.1097\/IGC.0b013e3182a1cf71_bb0065","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1158\/1078-0432.CCR-1029-3","article-title":"Pathology of ovarian cancers in BRCA1 and BRCA2 carriers","volume":"10","author":"Lakhani","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1097\/IGC.0b013e3182a1cf71_bb0070","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/00004347-200210000-00011","article-title":"Histopathologic features of genetically determined ovarian cancer","volume":"21","author":"Shaw","year":"2002","journal-title":"Int J Gynecol Pathol"},{"key":"10.1097\/IGC.0b013e3182a1cf71_bb0075","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1023\/A:1025700807451","article-title":"Histopathological characteristics of BRCA1-and BRCA2-associated intraperitoneal cancer: a clinic-based study","volume":"2","author":"Piek","year":"2003","journal-title":"Fam Cancer"},{"key":"10.1097\/IGC.0b013e3182a1cf71_bb0080","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1001\/jama.283.17.2260","article-title":"Clinicopathologic features of BRCA-linked and sporadic ovarian cancer","volume":"283","author":"Boyd","year":"2000","journal-title":"JAMA"},{"key":"10.1097\/IGC.0b013e3182a1cf71_bb0085","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1136\/jmg.2009.068130","article-title":"Survival in women with MMR mutations and ovarian cancer: a multicentre study in Lynch syndrome kindreds","volume":"47","author":"Grindedal","year":"2010","journal-title":"J Med Genet"},{"key":"10.1097\/IGC.0b013e3182a1cf71_bb0090","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s10549-010-0859-2","article-title":"Effect of BRCA1\/2 mutation on short-term and long-term breast cancer survival: a systematic review and meta-analysis","volume":"122","author":"Lee","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1097\/IGC.0b013e3182a1cf71_bb0095","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/cncr.21536","article-title":"BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases","volume":"104","author":"Pal","year":"2005","journal-title":"Cancer"},{"key":"10.1097\/IGC.0b013e3182a1cf71_bb0100","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1136\/ijgc-00009577-200509000-00008","article-title":"Favorable clinical behavior in young ovarian carcinoma patients: a rationale for conservative surgery?","volume":"15","author":"Sardi","year":"2005","journal-title":"Int J Gynecol Cancer"},{"key":"10.1097\/IGC.0b013e3182a1cf71_bb0105","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.2009.27.0660","article-title":"American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility","volume":"28","author":"Robson","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1097\/IGC.0b013e3182a1cf71_bb0110","first-page":"19","article-title":"Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive","volume":"29","author":"Casparie","year":"2007","journal-title":"Cell Oncol"},{"key":"10.1097\/IGC.0b013e3182a1cf71_bb0115","doi-asserted-by":"crossref","first-page":"18032","DOI":"10.1073\/pnas.1115052108","article-title":"Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing","volume":"108","author":"Walsh","year":"2011","journal-title":"Proc Natl Acad Sci U SA"},{"key":"10.1097\/IGC.0b013e3182a1cf71_bb0120","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1200\/JCO.2002.20.6.1480","article-title":"Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals","volume":"20","author":"Frank","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1097\/IGC.0b013e3182a1cf71_bb0125","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.1088759","article-title":"New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2","volume":"302","author":"King","year":"2003","journal-title":"Science"},{"key":"10.1097\/IGC.0b013e3182a1cf71_bb0130","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1097\/AOG.0b013e3181da08d7","article-title":"Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities","volume":"115","author":"Meyer","year":"2010","journal-title":"Obstet Gynecol"},{"key":"10.1097\/IGC.0b013e3182a1cf71_bb0135","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/AOG.0b013e31825f3576","article-title":"Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy","volume":"120","author":"Schrader","year":"2012","journal-title":"Obstet Gynecol"},{"key":"10.1097\/IGC.0b013e3182a1cf71_bb0140","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1200\/JCO.2008.16.1703","article-title":"\u201cBRCAness\u201d syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations","volume":"26","author":"Tan","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1097\/IGC.0b013e3182a1cf71_bb0145","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"10.1097\/IGC.0b013e3182a1cf71_bb0150","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"10.1097\/IGC.0b013e3182a1cf71_bb0155","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(10)60893-8","article-title":"Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial","volume":"376","author":"Audeh","year":"2010","journal-title":"Lancet"},{"key":"10.1097\/IGC.0b013e3182a1cf71_bb0160","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1097\/IGC.0b013e3182a1cf71_bb0165","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1200\/JCO.2009.26.9589","article-title":"Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval","volume":"28","author":"Fong","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24030561?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24030561?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.lww.com\/ijgc\/Fulltext\/10.1097\/IGC.0b013e3182a1cf71","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:09:24Z","timestamp":1753232964000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24030561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S1048891X24030561"],"URL":"https:\/\/doi.org\/10.1097\/igc.0b013e3182a1cf71","relation":{},"ISSN":["1048-891X"],"issn-type":[{"type":"print","value":"1048-891X"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Added Value of Family History in Counseling About Risk of BRCA1\/2 Mutation in Early-Onset Epithelial Ovarian Cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1097\/IGC.0b013e3182a1cf71","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright Copyright \u00a9 2013 by IGCS and ESGO","name":"copyright","label":"Copyright"}]}}